127 related articles for article (PubMed ID: 21356190)
1. Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Groves MJ; Sales M; Baker L; Griffiths M; Pratt N; Tauro S
Cancer Genet; 2011 Jan; 204(1):39-44. PubMed ID: 21356190
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic abnormalities in 532 patients with myeloid leukemias and myelodyplastic syndrome. The Czechoslovak MDS Cooperative Group.
Michalová K; Musilová J; Zemanová Z
Czech Med; 1990; 13(4):133-44. PubMed ID: 2081440
[TBL] [Abstract][Full Text] [Related]
3. Serial cytogenetic studies in allografted patients with chronic myeloid leukemia.
Bilhou-Nabera C; Bernard P; Marit G; Viard F; Gharbi MJ; Wen Z; Lacombe F; Broustet A; Reiffers J
Bone Marrow Transplant; 1992 Apr; 9(4):263-8. PubMed ID: 1600414
[TBL] [Abstract][Full Text] [Related]
4. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
5. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
[TBL] [Abstract][Full Text] [Related]
6. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
7. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.
Lin Y; Bruyère H; Horsman DE; Pantzar T; Barnett MJ; Hogge DE; Nevill TJ; Nantel SH; Sutherland HJ; Toze CL; Shepherd JD; Lavoie JC; Song KW; Smith CA; Forrest DL
Cancer Genet Cytogenet; 2006 Oct; 170(1):16-23. PubMed ID: 16965950
[TBL] [Abstract][Full Text] [Related]
8. [Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibtor-therapy].
Yuan T; Wang XY; Lai YY; Qin YZ; Shi HX; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):547-553. PubMed ID: 32397016
[No Abstract] [Full Text] [Related]
9. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
10. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
11. [Characteristics and outcome of chromosomal abnormalities in Ph negative cells of chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors].
Mu QT; Chen ZM; Lou JY; Cheng YZ; Wang YG; Jin J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Feb; 29(1):64-7. PubMed ID: 22311495
[TBL] [Abstract][Full Text] [Related]
12. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.
Soupir CP; Vergilio JA; Dal Cin P; Muzikansky A; Kantarjian H; Jones D; Hasserjian RP
Am J Clin Pathol; 2007 Apr; 127(4):642-50. PubMed ID: 17369142
[TBL] [Abstract][Full Text] [Related]
13. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
[TBL] [Abstract][Full Text] [Related]
14. [Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek].
Turkina AG; Kruglov SS; Druzhkova GA; Domracheva EV; Zakharova AV; Vinogradova OIu; Sysoeva EP; Diachenko LV; Chelysheva EIu; Zakharova ES; Abakumov EM; Kolosheĭnova TI; Kolosova LIu; Ivanova TV; Zhuravlev VS; Nemchenko IS; Zingerman BV; Kurova ES; Triputen' NZ; Loriia SS; Kovaleva LG; Khoroshko ND
Ter Arkh; 2005; 77(7):42-7. PubMed ID: 16116908
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic polyclonality in hematologic malignancies.
Johansson B; Billström R; Broberg K; Fioretos T; Nilsson PG; Ahlgren T; Malm C; Samuelsson BO; Mitelman F
Genes Chromosomes Cancer; 1999 Mar; 24(3):222-9. PubMed ID: 10451702
[TBL] [Abstract][Full Text] [Related]
16. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
17. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
Swolin B; Rödjer S; Westin J
Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
[TBL] [Abstract][Full Text] [Related]
18. [Abnormalities of chromosome 17 in myeloid malignancies with complex chromosomal abnormalities].
Zhu Y; Xu W; Liu Q; Pan J; Qiu H; Wang R; Qiao C; Jiang Y; Zhang S; Fan L; Zhang J; Shen Y; Xue Y; Li J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Oct; 25(5):579-82. PubMed ID: 18841577
[TBL] [Abstract][Full Text] [Related]
19. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
[TBL] [Abstract][Full Text] [Related]
20. Clonal chromosomal aberrations in Philadelphia negative cells such as monosomy 7 and trisomy 8 may persist for years with no impact on the long term outcome in patients with chronic myeloid leukemia.
Wasilewska EM; Panasiuk B; Gniot M; Sawicka A; Kozłowska K; Lewandowski K; Kłoczko J; Midro AT
Cancer Genet; 2017 Oct; 216-217():1-9. PubMed ID: 29025581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
